These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Axsome Therapeutics (AXSM), 268% surge in interest X4 Pharmaceuticals
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Axsome Therapeutics (AXSM), 268% surge in interest X4 Pharmaceuticals
Analyst John Newman of Canaccord Genuity maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), retaining the price target of $10.00. John Newman has given his Buy rating
Seres Therapeutics Inc. ( ($MCRB) ) has released its Q3 earnings. Here is a breakdown of the information Seres Therapeutics Inc. presented to its investors. Seres Therapeutics, Inc. is a
As of September 30, Seres Therapeutics (MCRB) had $66.8M in cash and cash equivalents. The company expects to fund operations into Q4 of 2025. It said, “Our SER-155 data provides
תיקון: Seres מדווחים על רווח למניה ברבעון השלישי מפעולות נמשכות של 33 סנט.